Online citations, reference lists, and bibliographies.
← Back to Search

Statins, High-density Lipoprotein Cholesterol, And Regression Of Coronary Atherosclerosis.

S. Nicholls, E. M. Tuzcu, I. Sipahi, A. W. Grasso, P. Schoenhagen, T. Hu, K. Wolski, T. Crowe, M. Desai, S. Hazen, S. Kapadia, S. Nissen
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
CONTEXT Statins reduce low-density lipoprotein cholesterol (LDL-C) levels and slow progression of coronary atherosclerosis. However, no data exist describing the relationship between statin-induced changes in high-density lipoprotein cholesterol (HDL-C) and disease progression. OBJECTIVE To investigate the relationship between changes in LDL-C and HDL-C levels and atheroma burden. DESIGN, SETTING, AND PATIENTS Post-hoc analysis combining raw data from 4 prospective randomized trials (performed in the United States, North America, Europe, and Australia between 1999 and 2005), in which 1455 patients with angiographic coronary disease underwent serial intravascular ultrasonography while receiving statin treatment for 18 months or for 24 months. Ultrasound analysis was performed in the same core laboratory for all of the studies. MAIN OUTCOME MEASURE Relationship between changes in lipoprotein levels and coronary artery atheroma volume. RESULTS During statin therapy, mean (SD) LDL-C levels were reduced from 124.0 (38.3) mg/dL (3.2 [0.99] mmol/L) to 87.5 (28.8) mg/dL (2.3 [0.75] mmol/L) (a 23.5% decrease; P<.001), and HDL-C levels increased from 42.5 (11.0) mg/dL (1.1 [0.28] mmol/L) to 45.1 (11.4) mg/dL (1.2 [0.29] mmol/L) (a 7.5% increase; P<.001). The ratio of LDL-C to HDL-C was reduced from a mean (SD) of 3.0 (1.1) to 2.1 (0.9) (a 26.7% decrease; P<.001). These changes were accompanied by a mean (SD) increase in percent atheroma volume from 39.7% (9.8%) to 40.1% (9.7%) (a 0.5% [3.9%] increase; P = .001) and a mean (SD) decrease in total atheroma volume of 2.4 (23.6) mm3 (P<.001). In univariate analysis, mean levels and treatment-mediated changes in LDL-C, total cholesterol, non-HDL cholesterol, apolipoprotein B, and ratio of apolipoprotein B to apolipoprotein A-I were significantly correlated with the rate of atherosclerotic progression, whereas treatment-mediated changes in HDL-C were inversely correlated with atheroma progression. In multivariate analysis, mean levels of LDL-C (beta coefficient, 0.11 [95% confidence interval, 0.07-0.15]) and increases in HDL-C (beta coefficient, -0.26 [95% confidence interval, -0.41 to -0.10]) remained independent predictors of atheroma regression. Substantial atheroma regression (> or =5% reduction in atheroma volume) was observed in patients with levels of LDL-C less than the mean (87.5 mg/dL) during treatment and percentage increases of HDL-C greater than the mean (7.5%; P<.001). No significant differences were found with regard to clinical events. CONCLUSIONS Statin therapy is associated with regression of coronary atherosclerosis when LDL-C is substantially reduced and HDL-C is increased by more than 7.5%. These findings suggest that statin benefits are derived from both reductions in atherogenic lipoprotein levels and increases in HDL-C, although it remains to be determined whether the atherosclerotic regression associated with these changes in lipid levels will translate to meaningful reductions in clinical events and improved clinical outcomes.
This paper references
10.1097/00019048-200106000-00021
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
S. Grundy (2001)
10.1161/CIRCULATIONAHA.105.565135
Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial
J. Otvos (2006)
10.1161/01.CIR.103.2.276
An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro
M. Aikawa (2001)
GEMFIBROZIL FOR THE SECONDARY PREVENTION OF CORONARY HEART DISEASE IN MEN WITH LOW LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL
Ander (2000)
An HMGCoAreductase inhibitor, cerivastatin, suppressesgrowth ofmacrophagesexpressingmatrixmetalloproteinasesand tissue factor in vivo and in vitro
M Aikawa (2001)
10.1016/j.accreview.2005.02.063
Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
S. Nissen (2004)
10.1161/01.CIR.0000133317.49796.0E
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
S. Grundy (2004)
10.1517/14656566.4.11.1901
Pharmacotherapy for dyslipidaemia – current therapies and future agents
H. Bays (2003)
HelsinkiHeartStudy : primary - prevention trialwithgemfibrozil inmiddle - aged men with dyslipidemia : safety of treatment , changes in risk factors , and incidence of coronary heart disease
EloO FrickMH (1987)
Scandinavian Simvastatin Survival Study Group
10.1016/S0140-6736(05)67667-2
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
A. Keech (2005)
10.1056/NEJM199906173402418
Atherosclerosis--an inflammatory disease.
Kenny J. Williams (1999)
10.1073/PNAS.91.20.9607
Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse.
A. Plump (1994)
10.1016/S0735-1097(86)80293-5
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
P. Canner (1986)
MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial.
S. Feasson (2008)
10.1056/NEJM199610033351401
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
F. Sacks (1996)
10.1161/01.ATV.0000163840.63685.0c
Statins Reduce Interleukin-6–Induced C-Reactive Protein in Human Hepatocytes: New Evidence for Direct Antiinflammatory Effects of Statins
C. Arnaud (2005)
10.1161/01.ATV.0000022850.59845.E0
Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study
G. Luc (2002)
Reading is important. Read between the lines—don't swallow everything. —Gwendolyn Brooks
(1917)
10.1001/JAMA.295.13.JPC60002
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
S. Nissen (2006)
10.1016/S0140-6736(94)90566-5
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Scandinavian Simvastatin Survival Study Group (1994)
HelsinkiHeartStudy : primaryprevention trialwithgemfibrozil inmiddleaged men with dyslipidemia : safety of treatment , changes in risk factors , and incidence of coronary heart disease
PL Canner (1987)
10.1161/01.CIR.0000140261.58966.A4
Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study
S. Okazaki (2004)
10.1097/01.IEB.0000142773.91809.E5
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
S. Nissen (2004)
10.1161/01.RES.0000146094.59640.13
Antiinflammatory Properties of HDL
P. Barter (2004)
10.1097/00019616-199605000-00022
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
TUART (2000)
10.3810/psm.2008.12.22
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
A. Taylor (2008)
10.1056/NEJMOA031766
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
M. Brousseau (2004)
10.1016/S0084-3873(08)70201-3
Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialKeech A, and the FIELD study investigators (Univ of Sydney, Australia; et al) Lancet 366:1849–1861, 2005§
W. Frishman (2007)
10.1097/01.AOG.0000133105.83326.47
Intensive versus moderate lipid lowering with statins after acute coronary syndromes*
M. Miller (2004)
10.1001/JAMA.1986.03380200061022
Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).
J. Stamler (1986)
10.1161/circ.106.25.3143
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
S. Grundy (2002)
10.1016/j.jvs.2005.04.037
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
J. Larosa (2005)
10.1172/JCI114558
Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.
J. Badimon (1990)
10.1161/01.CIR.102.1.21
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.
Bezafibrate Infarction Prevention study (2000)
10.1172/JCI10852
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
G. Martin (2001)
10.1056/nejmx060007
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
J. Auer (2004)
10.1161/01.CIR.0000148955.19792.8D
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins
A. Taylor (2004)
10.1001/JAMA.279.20.1615
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
J. R. Downs (1998)
10.1016/j.jvs.2005.01.024
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
S. Nissen (2005)
10.1001/JAMA.294.19.2437
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
T. Pedersen (2005)
10.1097/00008483-199603000-00012
Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia
R. Milani (1996)
Simvastatin and niacin, antioxidant vitamins, or the combination STATINS, LIPIDS, AND CORONARY ATHEROMA REGRESSION ©2007 American Medical Association
BG Brown (2007)
10.1056/NEJM199811053391902
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
A. Tonkin (1998)
10.1001/JAMA.290.17.2292
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.
S. Nissen (2003)
10.1161/01.ATV.20.1.189
Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
M. Guerin (2000)
10.1056/NEJMOA054699
Effect of ACAT inhibition on the progression of coronary atherosclerosis.
S. Nissen (2006)
10.1016/J.JACC.2005.05.086
The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes.
K. Ray (2005)
10.1056/NEJM199511163332001
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
J. Shepherd (1995)
10.1016/S0735-1097(01)01175-5
American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
G. Mintz (2001)
10.1016/S0140-6736(00)04209-4
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study
Diabetes Atherosclerosis Intervention Study Investigators (2001)
10.1056/NEJM198711123172001
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
M. Frick (1987)
El tratamiento hipolipemiante intensivo frente al moderado con estatinas tras síndromes coronarios agudos
C. Cannon (2004)
10.1016/J.ATHEROSCLEROSISSUP.2004.08.027
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.
T. Pedersen (2004)
10.1056/NEJMOA011090
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
B. Brown (2001)
10.1016/j.jvs.2005.01.030
C-reactive protein levels and outcomes after statin therapy.
P. Ridker (2005)
10.1097/00008483-199701000-00013
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
ohn (2000)
10.1016/s1062-1458(02)00911-x
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary
S. Yusuf (2002)
10.1161/01.CIR.0000135215.75876.41
Regression of Coronary Atherosclerosis by Simvastatin: A Serial Intravascular Ultrasound Study
L. Jensen (2004)



This paper is referenced by
L'imaging della placca vulnerabile
G. Guagliumi (2010)
10.1161/CIRCRESAHA.109.211201
Short Communication: Dating Components of Human Atherosclerotic Plaques
Isabel Gonçalves (2010)
10.7793/JCORON.18.476
Multi detector-row computed tomographyにて冠動脈有意狭窄病変のない症例の予測因子についての検討
俊介 木内 (2012)
10.7793/JCORON.23.031
Angioscopic assessment for post coronary bypass saphenous vein diseases: ~内視鏡所見による検討~
Mitsumasa Hata (2017)
10.1016/j.carrev.2016.12.002
Late-breaking Trials from the 2016 American Heart Association's Scientific Sessions.
Kyle D. Buchanan (2017)
10.1371/journal.pone.0098368
A Pro-Atherogenic HDL Profile in Coronary Heart Disease Patients: An iTRAQ Labelling-Based Proteomic Approach
L. Yan (2014)
10.1155/2012/508683
The Evaluation of Chinese Therapeutic Food for the Treatment of Moderate Dyslipidemia
S. Sun (2012)
10.1139/y11-118
Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407.
T. Korolenko (2012)
10.1155/2011/928386
Morphological Changes of Parotid Gland in Experimental Hyperlipidemia
Ioanna D. Daskala (2011)
10.1007/978-94-024-1222-2_2
Medicinal Uses of Soil Components, Geophagia and Podoconiosis
R. Nieder (2018)
10.1097/MCA.0000000000000408
The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications
J. Feig (2016)
10.5551/JAT.9183
Usefulness of LDL-C-related parameters to predict cardiovascular risk and effect of pravastatin in mild-to-moderate hypercholesterolemia.
K. Mizuno (2012)
10.1002/clc.20944
HDL‐C Levels and Revascularization Procedures in Coronary Heart Disease Patients Treated With Statins to Target LDL‐C Levels
A. Elis (2011)
10.1016/j.jcct.2010.03.005
Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study.
S. Voros (2010)
10.1016/S0214-9168(10)70005-X
Cocientes lipoproteicos: significado fisiológico y utilidad clínica de los índices aterogénicos en prevención cardiovascular
J. Millán (2010)
10.1007/s12325-009-0025-6
Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?
G. Fabbri (2009)
10.1016/S1098-3597(07)80011-1
High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome.
C. Cannon (2007)
10.1007/S11883-007-0031-6
The strengths and limitations of the ApoB/ApoA-I ratio to predict the risk of vascular disease: a hegelian analysis
A. Sniderman (2007)
10.1016/S0828-282X(08)71035-3
Treatment of low high-density lipoprotein cholesterol
Z. Awan (2008)
Best Practice & Research Clinical Endocrinology & Metabolism
B. Stratmann (2009)
10.2174/187152509789541918
Gene-activators prevent and regress atherosclerosis and reduce mortality.
Pauli V. Luoma (2009)
10.7600/JSPFSM.61.251
Fitness level and physical capacity of commuter cyclists and the actual condition while cycling to work in Tokai region
Takumi Nishii (2012)
10.25040/AML2017.03.072
Calculated parameters of the lipidogram: modern scientific views and correlations with laboratory and instrumental indexes
Larysa Strilchuk (2017)
10.1016/j.bbrc.2019.07.060
Plasma kallikrein contributes to ambient particulate matter-induced lung injury.
B. Wang (2019)
10.1507/ENDOCRJ.K11E-080
Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease.
M. Abe (2011)
10.1016/j.redox.2017.11.027
Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1
D. He (2018)
10.1007/978-3-540-79088-4_18
Androgenic anabolic steroid abuse and the cardiovascular system.
P. Vanberg (2010)
ФАРМАКОЛОГИЧЕСКАЯ КОРРЕКЦИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ И АТЕРОГЕННЫХ ПОВРЕЖДЕНИЙ: ВОЗМОЖНОСТИ ВОССТАНОВЛЕНИЯ СТРУКТУРЫ И МЕТАБОЛИЗМА СЕРДЕЧНОЙ МЫШЦЫ
E. I. Yuzhik (2013)
10.1007/BF03256582
Effects on Coronary Atherosclerosis by Targeting Low-Density Lipoprotein Cholesterol with Statins
J. Ferrières (2009)
10.1007/978-1-4419-1387-6_30
Prevention of Lesion Recurrence in Endovascular Devices
A. Rochier (2010)
10.1159/000356856
Cholesterol: The Good, the Bad, and the Ugly – Therapeutic Targets for the Treatment of Dyslipidemia
N. Elshourbagy (2013)
Srce i krvni Sudovi
B. Beleslin (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar